Production of freeze-dried human antihaemophilic cryoprecipitate.
نویسندگان
چکیده
منابع مشابه
Production of freeze-dried human antihaemophilic cryoprecipitate.
Concentration of factor VIII from fresh plasma by cryoprecipitation remains the basis for preparation of products used to treat haemophilia A. This paper describes the preparation of a factor VIII concentrate from small plasma pools in transfusion centres with drying facilities. The dried concentrate from one litre of plasma dissolves very well in 50 or 100 ml of distilled water and contains ar...
متن کاملFreeze dried cryoprecipitate: a clinical evaluation.
Freeze dried cryoprecipitate was used in the treatment of 14 patients with haemophilia A. The in vivo recovery was 91.2% which is comparable to that reported from other parts of Europe. The product was efficacious and no adverse effects were reported. Freeze dried cryoprecipitate is the high yield product of a low technology process and as such may be of value in reducing any possible shortfall...
متن کاملInfluence of heat treatment on FVIII:C recovery from freeze dried cryoprecipitate.
A standard lyophilised triple cryoprecipitate preparation, stabilised by the addition of Synthamin 17, was heat treated at 60 degrees C for 48 hours. The total protein content, factor VIII concentration, and factor VIII recovery were not affected by the heat treatment procedure. Heat treatment did not influence the reconstitution characteristics of the freeze dried preparation and there were no...
متن کاملEstablishment of Blastocyst Production System with Freeze-dried Bull Spermatozoa
25 Introduction 25 Materials and methods 27 Results 32 Discussion 35 Chapter 4: Procedure for bovine ICSI, not sperm freeze-drying, impairs the function of the microtubule-organizing center 39 Abstract 39 Introduction 39 Materials and methods 40 Results 43 Discussion 47 Chapter 5: Adverse effect of cake collapse on the functional integrity of freeze-dried bull spermatozoa 49 Abstract 49 Introdu...
متن کاملFreeze-dried B.C.G.
Freeze-dried B.C.G. of British manufacture became available for experimental work in 1955. The main reason for introducing it was the need for a vaccine which would retain its potency under conditions of prolonged storage. On reconstitution for injection the vaccine should produce a uniform suspension with minimal clumping, resulting in a uniform viable bacterial count. These properties mean th...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Clinical Pathology
سال: 1981
ISSN: 0021-9746
DOI: 10.1136/jcp.34.10.1091